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Translational studies involving the reuse and association of drugs are approaches that
can result in higher success rates in the discovery and development of drugs for serious
public health problems, including leishmaniasis. If we consider the number of
pathogenic species in relation to therapeutic options, this arsenal is still small, and
each drug possesses a disadvantage in terms of toxicity, efficacy, price, or treatment
regimen. In the search for new drugs, we performed a drug screening of L.
amazonensis promastigotes and intracellular amastigotes of fifty available drugs
belonging to several classes according to their pharmacophoric group.
Spironolactone, a potassium-sparing diuretic, proved to be the most promising
drug candidate. After demonstrating the in vitro antileishmanial activity, we
evaluated the efficacy on a murine experimental model with L. amazonensis and L.
infantum. The treatment controlled the cutaneous lesion and reduced the parasite
burden of L. amazonensis significantly, as effectively as meglumine antimoniate. The
treatment of experimental visceral leishmaniasis was effective in reducing the parasite
load on the main affected organs (spleen and liver) via high doses of spironolactone.
The association between spironolactone and meglumine antimoniate promoted better
control of the parasite load in the spleen and liver compared to the group treated with
meglumine antimoniate alone. These results reveal a possible benefit of the concomitant use
of spironolactone and meglumine antimoniate that should be studied more in depth for the
future possibility of repositioning for leishmaniasis co-therapy.
Keywords: spironolactone, drug repositioning, leishmania, visceral leishmaniasis, pentavalent antimonial
INTRODUCTION
In 2018, among the 200 countries or territories that sent reports to the World Health Organization,
88 were considered endemic for cutaneous leishmaniasis (CL) and 78 were considered endemic for
visceral leishmaniasis (VL) (WHOControl of Neglected Tropical Diseases, 2020). It is considered the
third most common parasitic disease, after schistosomiasis and malaria, based on morbidity and
disability-adjusted life years (DALYs) (GBD 2015 DALYs and HALE Collaborators, 2016). Because
of its widespread occurrence, predominantly in the poorest social strata, leishmaniasis is among the most
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neglected diseases, with very limited investment in diagnosis,
treatment, and control (Sunyoto et al., 2019).
Currently, leishmaniasis is treated with a small arsenal of
drugs, including pentavalent antimonials, amphotericin B
deoxycholate, lipid formulations of amphotericin B,
miltefosine, and paromomycin, all of which have
disadvantages in terms of toxicity, efficacy, price, or treatment
regimen (Agil, 2015). The development of cheaper, safer, and
orally available drugs is urgently needed. One way to accelerate
this process is the well-known strategy of “old drug, new use
research.” Drugs that are currently on the market have already
undergone pharmacokinetic and toxicity testing and have been
proven to be clinically safe, thus obviating the problematic testing
bottleneck of the drug discovery pipeline. One recent example of
the successful use of this approach is the demonstration of
fexinidazole’s leishmanicidal activity in vitro and in vivo
against Leishmania infantum, L. amazonensis, and L.
braziliensis (Wyllie et al., 2012; de Morais-Teixeira et al., 2019).
Moreover, a recent revision paper published by our group
demonstrated that several studies aiming at repurposing drugs for
leishmaniasis have been carried out, comprising around 83 drugs
(Andrade-Neto et al., 2018). Our group also performed a
screening of fifty available drugs belonging to several
pharmacological categories; of these, spironolactone
(Figure 1), a potassium-sparing diuretic that acts as an
aldosterone receptor antagonist, proved to be the most
promising drug candidate. Spironolactone was developed in
the 1950s, and it is licensed for the treatment of hypertension,
heart failure, hypokalemia, and other morbidities (Wile, 2012). In
this study, we describe the leishmanicidal activity of
spironolactone in vitro and its efficacy in treatment alone or
in co-therapy with the meglumine antimoniate of experimental
cutaneous and visceral leishmaniasis.
MATERIALS AND METHODS
Parasite
Promastigotes of Leishmania amazonensis (strain MHOM/BR/
77/LTB 0016) and Leishmania infantum (strain MHOM/MA/67/
ITMAP-263) were maintained at 26°C in Schneider’s insect
medium (Sigma–Aldrich, St Louis, MO, United States) with
10% or 20% serum, respectively, with 100 μg/ml streptomycin
and 100 U/mL penicillin until the fifth passage. Afterward, old




Promastigotes of L. amazonensis and L. infantum at 1 × 106 cells/
ml were incubated with spironolactone (0–50 μM) or canrenoate
(0–128 μM) for 72 h at 26°C. The assays were performed in
triplicate in 96-well plates (Costar, New York, United States).
Inhibition parasite growth was assessed by a fluorescent assay,
Resazurin (Sigma-Aldrich) (Faiões et al., 2018). Briefly, 50 µM of
resazurin was added per well, and then the samples were
incubated for an additional 2 h. The fluorescence was measured
using a Spectra Max GEMINI XPS spectrofluorometer
(Molecular Devices, Silicon Valley, United States) at excitation
and emission wavelengths of 560 and 590 nm, respectively. The
concentration effect curve was fitted for antipromastigote testing
via nonlinear regression using Graph Pad Prism 7.0. Finally, the
IC50 value was determined.
Antiamastigote activity
Resident macrophages from BALB/c mice were obtained by
peritoneal lavage with 5 ml of cold RPMI medium (Sigma-
Aldrich). The cell suspension was adjusted to a 2 × 106/ml
concentration and plated in LAB-TEK chambers (Nunc). After
1 h, the cultures were washed with phosphate-buffered saline
(PBS) at 37°C to remove non-adherent cells. The remaining cells
were incubated at 37°C/5% CO2 with promastigotes of L.
amazonensis at a ratio of 3:1 or L. infantum at a ratio of 5:1.
After 3 h, the chambers were rewashed to remove free parasites.
The monolayers were incubated with spironolactone (0, 2.5, 5.0,
and 10.0 µM) or canrenoate (0, 2.0, 4.0, 8.0, and 16 µM) for
72 h at 37°C/5% CO2. The antiamastigote activity was evaluated
microscopically after staining the chambers with the Instant Prov
hematological dye system (Newprov, Curitiba, Brazil); at least 100
macrophages were counted per sample. The results were
expressed as the infection index (IF) using the following
formula: IF  % infected cells X (number of amastigotes/total
macrophages). The concentration effect curve was fitted for the
antiamastigote test via nonlinear regression using Graph Pad
Prism 7.0, and the IC50 value was determined.
Cytotoxicity in Murine Macrophages
Mouse peritoneal macrophages in 96-well plates were treated
with spironolactone and canrenoate (16–256 μM) for 72 h at
37°C/5% CO2. After removing the supernatant, viable cells
were quantified by adding resazurin in phosphate buffer saline
(PBS), a final concentration of 50 μM, and then the samples were
incubated for an additional 2 h. The fluorescence was measured
using a Spectra Max GEMINI XPS spectrofluorometer
(Molecular Devices, Silicon Valley, United States) at excitation
and emission wavelengths of 560 and 590 nm, respectively. The
percentage of viable cells was calculated relative to the control
cells. The cytotoxic concentrations lethal to 50% of the cells
FIGURE 1 | Structure of spironolactone.
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(CC50) were obtained by nonlinear regression of the sigmoid
growth curves using the Graph Pad Prism 7.0 software.
Ethics Statement
BALB/c mice were obtained from the Oswaldo Cruz
Foundation (FIOCRUZ) animal facilities (Rio de Janeiro,
Brazil). The mice were housed in a maximum of four per
cage and kept in a conventional room (23 ± 2°C, relative
humidity: 60%, with 12 h light-dark cycles). The animals
were provided with sterilized water and chow ad libitum.
Studies in L. amazonensis and L. infantum-infected BALB/c
mice were performed following the guidelines of the Guide for
the Care and Use of Laboratory Animals of the Brazilian
National Council of Animal Experimentation (COBEA).
This study was approved by the Animal Ethics Committee
of Oswaldo Cruz Institute (L26/2015).
In vivo Studies
Murine model of the Cutaneous Leishmaniasis
BALB/c mice (four per group) were infected in the right ear with
2 × 106 promastigotes of L. amazonensis in the stationary phase of
growth. Treatment was started seven days after infection. The
dose was calculated based on the minimum recommended dose
for humans (50 mg/day) and on an adaptation of the formula
suggested by Reagan-Shaw et al., as follows: animal dose (mg/kg)
 (human Km/animal Km) × human dose (mg/kg), where mouse
Km  3, human Km  37, and human weight  70 kg (Reagan-Shaw
et al., 2008). The animals were treated orally through an orogastric
tube with a suspension of 8.8mg of spironolactone/kg/day diluted in
PBS containing 2% DMSO or were treated intraperitoneally with
30mg SB5+/kg/day of meglumine antimoniate; the control mice were
given PBS containing 2% DMSO. All animals were treated five times
per week for 6 weeks. The disease’s course was monitored by
measuring the thickness of the infected ear with a caliper
(Mitutoyo, São Paulo, Brazil) every 3 or 4 days for 49 days.
At the end of the experiment, the animals were euthanized by
controlled CO2 inhalation. Ears containing the lesions were
removed to analyze the parasite load by limiting dilution analysis
(LDA), as described previously (da Cunha-Júnior et al., 2011).
Tissues were macerated in Schneider medium containing 10%
FBS. The cell suspensions were then adjusted to 10mg tissue/mL
in triplicate andwere serially diluted 1:2 in 96-well plates, resulting in
a final volume of 200 μL/well. The cultures were observed for seven
days using an inverted optical microscope to determine the lowest
dilution containing parasites. The parasite load was expressed as the
number of parasites/mg of tissue. A two-way ANOVA with a
Bonferroni post-test was applied in the data analysis.
Murine Model of Visceral Leishmaniasis
BALB/c mice were infected intraperitoneally with 1.0 × 108
promastigotes of L. infantum stationary phase. Seven days
after infection, once the infection had already been established
(Cunha-Júnior et al., 2016), treatment with spironolactone was
introduced daily in three different doses of 4.4, 8.8, and
17.6 mg/kg/day. Control groups were treated with meglumine
antimoniate (28 mg/kg/day of Sb5+) intraperitoneally. To
determine the association between spironolactone and
meglumine antimoniate, a fixed dose of meglumine
antimoniate was used (28 mg/kg/day of Sb5+). After 23 days of
treatment, the animals were euthanatized in a CO2 chamber, and
the organs of interest (liver and spleen) were aseptically removed,
weighed, and homogenized in Schneider’s medium supplemented
with 20% HIFCS. The parasitic load was estimated using a
parasite LDA. Briefly, the resulting cell suspensions were
serially diluted and evaluated by limiting dilution analysis after
7 days (Buffet et al., 1995). The number of parasites/organs was
calculated as follows (geometric mean of titer from triplicate
cultures) × (common fraction of the homogenized organ added to
the first well) × (weight of organ in mg).
RESULTS
In vitro Activity
The direct antileishmanial activity of spironolactone was first
evaluated by incubating L. amazonensis or L. infantum
promastigotes with the drug for 72 h. Spironolactone was a
potent inhibitor of parasite growth, with an IC50 of 3.6 and
28.6 μM, respectively (Table 1). Next, we evaluated the
spironolactone activity against the mammalian evolutive form
of the parasite. Spironolactone was found to be active against
intracellular amastigotes, with an IC50 of 1.8 µM for L.
amazonensis and 18.0 µM for L. infantum (Table 1). The CC50
of spironolactone for peritoneal murine macrophages was
150 μM, demonstrating a selectivity index (SI) of 83.3 and 8.3
for L. amazonensis and L. infantum, respectively (Table 1). Then,
we evaluated one of the spironolactone metabolites (potassium
canrenoate) against Leishmania amazonensis. Interestingly,
canrenoate, even at the highest concentration tested (128 μM),
was not active against promastigotes but showed an IC50 of 7.6 µM
in intracellular amastigotes, with less cytotoxicity (>256 µM) in
macrophages compared to spironolactone (Table 1).
In vivo Efficacy
After demonstrating the in vitro antileishmanial activity, we
evaluated the efficacy on a murine experimental model of
leishmaniasis using L. amazonensis or L. infantum.
Spironolactone, orally delivered at 8.8 mg/kg five times per week
(6 weeks–30 doses), was effective in controlling lesion development
from the third week (Figure 2) and the parasite burden (insert
Figure 2) in mice. There was no significant difference in either
parameter evaluated between the treatment of spironolactone orally
and meglumine antimoniate intraperitoneally.
Experimental visceral leishmaniasis was evaluated in L.
infantum-infected BALB/c mice. Treatment using 17.6 mg/kg/
day of spironolactone was effective in reducing the parasite load
on the main affected organs (spleen and liver) (Figures 3A,B).
However, it was less effective than the antimonial. To evaluate the
benefit of the concomitant use of potassium-sparing diuretic with
meglumine antimoniate, we associated the effective dose of
meglumine antimoniate with the two lower doses of
spironolactone (4.4mg/kg/day and 8.8mg/kg/day). The association
promoted better control of the parasite load in the spleen
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compared with the antimonial alone (98 % × 90 % of reduction of
the parasite load, respectively). In the liver, we noted a reduction of
97% in the group treated with meglumine antimoniate, while the
association reduced 100% of the parasite load (Figures 3C,D).
DISCUSSION
Drug development is a long and expensive process, taking on
average fifteen years of massive investment to generate a product.
In leishmaniasis, there was a 60-years gap between the release of
pentavalent antimonials and the release of miltefosine (Dorlo
et al., 2012; Sundar and Singh, 2016). The development of
miltefosine, new formulations of conventional drugs, and
combination treatments in recent years have represented a
breakthrough for the chemotherapy of leishmaniasis. However,
little impact has been observed in endemic areas, which can partly
be explained by the high cost of these new alternatives, hindering
their use in developing countries (Dorlo et al., 2012). Thus,
repositioning drugs seems a suitable tool to search for new
therapeutic options for the treatment of neglected diseases.
Here, we present the results of a project that aimed to study the
antileishmanial activity of drugs currently used for other
pathologies. Spironolactone, the most promising of these
drugs, exhibited IC50 values of 1.8 and 18.0 µM against the
intracellular amastigotes of L. amazonensis and L. infantum,
respectively (Table 1). Approximately 79% of the orally
administered dose of spironolactone in humans is converted
into canrenone, the most biologically active metabolite
described for this drug (Gómez et al., 2005). This metabolite is
hydrolyzed in its c-lactone ring, generating canrenoate (soluble in
water). After equilibrium, it reaches plasma concentrations like
canrenone (Karim, 1978). The reverse also occurs; Karim et al.
(1971) demonstrated that after intravenous administration of
potassium canrenoate, lactonization of the hydroxy acid group of
the canrenoate occurs, producing the c-lactone ring of the
canrenone. In 3 h, equal concentrations of these two
metabolites have already been found in plasma (Karim et al.,
1971). We evaluated the activity of canrenoate and found that this
metabolite demonstrates no activity against the promastigotes of
L. amazonensis but remains active against intracellular
amastigotes, although slightly less potent.
TABLE 1 | IC50 values for spironolactone and metabolite canrenoate on L. amazonensis and L. infantum promastigotes and intracellular amastigotes and CC50 values for
murine peritoneal macrophages and the selectivity index (SI).
Murine macrophage
CC50 (µM)










Spironolactone 150.0 ± 3.4 3.6 ± 1.0 1.8 ± 0.7 83.3 28.6 ± 2.2 18.0 ± 1.1 8.3
Canrenoate >256 >128 7.6 ± 2.3 >34.6 NT NT —
Values represent the mean ± SE of three different experiments. NT–not tested.
FIGURE 2 | Efficacy of oral spironolactone against murine cutaneous leishmaniasis. BALB/c mice were infected subcutaneously in the right ear with 2 × 106
promastigotes of L. amazonensis. All animals were treated five days/week for six weeks. Spironolactone at 8.8 mg/kg/day was diluted in PBS containing 2%DMSO and
was given orally; meglumine antimoniate (30 mg/kg/day of the Sb5+) or PBS containing 2% DMSO was injected intraperitoneally in the right lower quadrant of the
abdomen. The lesion development was monitored two times a week, measuring the infected ear with a caliper. At the end of the treatment, the animals were
euthanized, and the parasite load was estimated by limiting dilution analysis (insert). Data are represented as the means ± standard error of four animals per group.
*p < 0.05, **p < 0.01, and ***p < 0.001 in treated groups x control group.
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After demonstrating the in vitro selectivity of spironolactone,
its ability to control the development of cutaneous leishmaniasis
was evaluated. The infection of BALB/c mice with L. amazonensis
is well established in the literature as a model of extreme
susceptibility, with progressive swelling at the inoculation site
accompanied by ulceration and metastasis (Neal and Hale, 1983).
Oral treatment with spironolactone effectively controlled the
development of the lesion and reduced the parasite load, with
activity similar to that of meglumine antimoniate, which was
administered intraperitoneally (Figure 2). Spironolactone treatment
in the visceral leishmaniasis model showed efficacy, and the
combination with meglumine antimoniate was promising. The
combination of meglumine antimoniate with 8.8mg/kg/day of
spironolactone was more effective than treatment with meglumine
antimoniate alone. Some studies have shown that the use ofmeglumine
antimoniate associated with other drugs is effective; for example,
combinations with lapachone derivatives, azoles, amiodarone, and
aminosidine sulfate have shown a greater effectiveness when
compared to the use of meglumine antimoniate alone (Oliva et al.,
1998; Anversa et al., 2017; Gonçalves-Oliveira et al., 2019).
Giannitrapani et al. (2009) described the case of a patient with
visceral leishmaniasis who was previously diagnosed with
cirrhosis. He was referred on admission for previous treatment
with spironolactone and vitamin K. The disease was advanced,
and therapy with liposomal amphotericin B was instituted with
good response. As it was not a controlled study, no conclusions
can be drawn about how spironolactone influenced the
development of the disease. In addition, data on dosage and
treatment regimen were not mentioned. It is worth mentioning
that spironolactone has contraindications for patients with
anuria, acute renal failure, significant impairment of renal
excretory function, or hyperkalemia. Thus, it should be used
with caution in some cases, as described in the product
monograph (Pfizer, 2015).
Spironolactone has a nucleus like other spirolactones, which
are described as inhibitors of 17β-hydroxysteroid dehydrogenase
(17β-HSD), an enzyme involved in the last stage of cholesterol
biosynthesis (Poirier et al., 2001). In addition, spironolactone has
also been implicated as an inhibitor of CYP90B1, which is
responsible for the biosynthesis of brassinosteroid
phytohormone in plants (Asami et al., 2004; Bajguz et al.,
2020). Thus, a possible mechanism of antileishmania activity
of this drug is interference in the sterol biosynthesis of the
parasite. This pathway is considered essential since its
pharmacological inhibition results in the death of the parasite
(Roberts et al., 2003). However, specific experiments to evaluate
this hypothesis must be carried out.
In conclusion, these results demonstrate a remarkable effect of
spironolactone on murine cutaneous and visceral leishmaniasis.
Additional studies are needed to determine the activity of
spironolactone against other Leishmania species to optimize the
therapeutic regimen and to determine its mechanism of action.
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FIGURE 3 | Efficacy of oral spironolactone alone (A,B) and its association with meglumine antimoniate (C,D) in Experimental Visceral Leishmaniasis. BALB/c mice
(8 per group) were infected intraperitoneally with 1.0 × 108 promastigotes of stationary phase L. infantum. Seven days after infection, the animals were treated with
spironolactone in three different doses of 4.4, 8.8, and 17.6 mg/kg/day along with meglumine antimoniate (28 mg/kg/day of Sb5+) by intraperitoneal route. The control
group was treated with the vehicle via an oral route (PBS containing 2% DMSO). Regarding the association between spironolactone and meglumine antimoniate, a
fixed dose of meglumine antimoniate (28 mg/kg/day of Sb5+) was used with 4.4 or 8.8 mg/kg/day of spironolactone. After 23 days of treatment, the animals were
euthanized in a CO2 chamber, and the spleen (panels A and C) and liver (panels B andD) were aseptically removed, weighed, and homogenized. The parasite load was
estimated using the limiting dilution assay. Data are presented as means ± standard error of 8 animals per group; *p < 0.05 and ***p < 0.001; CI: control infected; S:
spironolactone; and G: meglumine antimoniate.
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